FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
NI.	ame and Address of Departing Decem

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol BELLICUM PHARMACEUTICALS, INC								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Farrell Thomas J.						BLCM]								X Director		10%	Owner		
(Last) (First) (Middle)						[BEGIN]								X	X Officer (give title below)		Other below	(specify	
C/O BELLICUM PHARMACEUTICALS, INC.							3. Date of Earliest Transaction (Month/Day/Year)								President and CEO				
2130 W. HOLCOMBE BLVD., STE. 800						09/01/2015													
2130 W. HOLCOMIDE BLVD., STE. 000							If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable				
(Street)					""	II / III of the control of the co								Line)					
HOUSTON TX 77030													X Form filed by One Reporting Person						
					-									Form filed by More than One Reporting Person					
(City)	(St	ate) (Zip)																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transactio Date (Month/Day/N						Execution Date,			3. Transaction Code (Instr. 8)					nd 5) Secur Benef Owne		icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price	Tra		rted action(s) 3 and 4)		(Instr. 4)	
Common Stock 09/01/20)15			S ⁽¹⁾		2,500	D	\$16.7	\$16.777(2)		66,362	D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security 3. Transaction Date Execution Date, if any (Month/Day/Year)		ion Date,		Transaction Code (Instr. 3)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date			and t of ies ying ive y (Instr. 3 Amount or Number of Shares	-		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person on March 26, 2015.
- 2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.42 to \$17.0909. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Remarks:

/s/ Thomas J. Farrell

09/03/2015

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.